Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

86.92 -1.57 (-1.78%)
Streaming Delayed Price Updated: 1:33 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 467,041
Open 88.20
Bid (Size) 86.87 (3)
Ask (Size) 86.94 (2)
Prev. Close 88.49
Today's Range 86.40 - 88.45
52wk Range 70.73 - 117.77
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga

Performance

YTD
-13.61%
-13.61%
1 Month
-10.38%
-10.38%
3 Month
-15.81%
-15.81%
6 Month
-11.90%
-11.90%
1 Year
+15.69%
+15.69%

More News

Read More
3 Biotech Stocks With Blockbuster Potential
Via InvestorPlace
Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals
Via Investor's Business Daily
Death Cross Looms Over Biomarin Pharmaceutical Investors
Via Benzinga
What 17 Analyst Ratings Have To Say About Biomarin Pharmaceutical
Via Benzinga
A Preview Of Biomarin Pharmaceutical's Earnings
Via Benzinga
Where Biomarin Pharmaceutical Stands With Analysts
Via Benzinga
Preview: Biomarin Pharmaceutical's Earnings
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
Via InvestorPlace
BioMarin Pharmaceutical Stock Shows Rising Relative Strength
Via Investor's Business Daily
3 "Expensive" Growth Stocks That Are a Lot Cheaper Than You Realize
Via The Motley Fool
BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74
Via Investor's Business Daily
Analyst Ratings for Biomarin Pharmaceutical
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Why did Sarepta Therapeutics Stock Plummet?
Via MarketBeat
Exposures Product Safety
After FDA Delays Hemophilia Gene Therapy, BioMarin's Dwarfism Drug Under FDA Review For Expanded Use
Via Benzinga
Why BioMarin Shares Are Plunging Today?
Via Benzinga
BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study
Via Investor's Business Daily
Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating
Via Investor's Business Daily
uniQure Stock Trying To Close In On Key Technical Measure
Via Investor's Business Daily
BioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
Via Benzinga
Earnings Scheduled For February 27, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.